back to press releases

Quanterix Leads Discussion At 4th Annual Slas Conference And Exhibition

Lexington, MA – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that they will be recognized as a SLAS Innovation Award finalist. The annual SLAS Innovation Award recognizes extraordinary achievement in innovative laboratory science and technology. Quanterix executives will also be highlighted as industry experts, presenting both a special session and serving as expert consultants on Innovation AveNEW, an area of the SLAS2015 Exhibition featuring a select group of up-and-coming scientific technology companies. SLAS2015 will be held February 7-11, 2015, at the Walter E. Washington Convention Center in Washington, D.C.

“We are honored that Quanterix is being recognized for this prestigious award, and to be presenting at the annual SLAS conference,” said Kevin Hrusovsky, Executive Chairman, Quanterix. “This validates the exciting work Quanterix is doing with our ground-breaking ultrasensitive Simoa technology. We are very appreciative of SLAS’ support for the opportunity it provides us to further the understanding of how our single molecule array technology can unlock a world of insight into disease detection, diagnosis and patient treatment.”

Quanterix executives will also be presenting at the following times during the conference:

  • The Simoa HD-1 Analyzer: A Fully-Automated, Multiplexed Immunoanalyzer With Single Molecule Sensitivity
    Who: Dr. David C. Duffy, Vice President, Research and Chief Technology Officer, Quanterix
    When: Tuesday, February 10 from 10:30 – 11:00am ET
    Where: Walter E. Washington Convention Center, Room 152
    What: Duffy will describe Simoa, a fully-automated instrument that allows multiple proteins to be detected at concentrations 1000-fold lower than is possible with standard immunoassay technologies. He will illustrate the use of Simoa for the detection of protein biomarkers at femtomolar concentrations for applications in inflammation, oncology, neurological diseases, and infectious diseases, explaining how, researchers can explore biomarkers and pathways with greater sensitivity and precision, paving the way for the development of new diagnostic tests and improved treatment of diseases. As a finalist in the SLAS Innovation Award, Duffy’s presentation will be evaluated by members of the judging panel.
  • The Commercialization of Laboratory Technologies: From Ideas to Reality, “Shark Tank to Compelling Valuation”
    Who: Kevin Hrusovsky, Executive Chairman, Quanterix
    When: Monday, February 9 from 4:00-4:30pm ET
    Where: Walter E. Washington Convention Center, Room 152A
    What: Hrusovsky will explore proven methodologies for commercializing disruptive life science innovation into compelling investor valuation and exits. He will discuss the importance of greater purpose, leadership and organizational culture as well as market immersion, strategy and navigating the treacherous landscape of “implementation and execution.” A five step process for translating disruptive innovation into investor value will be outlined.

For more information about SLAS2015, please visit: www.slas2015.org.

About The Society for Laboratory Automation and Screening

The Society for Laboratory Automation and Screening (SLAS) is an international community of more than 15,000 individual scientists, engineers, researchers, technologists and others from academic, government and commercial laboratories. The SLAS mission is to be the preeminent global organization providing forums for education and information exchange and to encourage the study of, and improve the practice of laboratory science and technology. For more information, visit www.SLAS.org.

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.Quanterix.com.

Media Contact

Nikki Festa & Caitlyn Keating
PAN Communications
617-502-4300
quanterix@pancomm.com

Download the Paper